Dating Foreign Women Can be a Rewarding and Enhancing Experience
Dating a overseas woman see page is a fascinating and rewarding experience. Nevertheless, it is important to be aware of cultural variations. For case, views toward marriage and home, identity…
DePuy Synthes Receives FDA Clearance for TriLEAP™ Lower Extremity Anatomic Plating System
DePuy Synthes Receives FDA Clearance for TriLEAP™ Lower Extremity Anatomic Plating System Today, Johnson & Johnson MedTech* announced that DePuy Synthes, The Orthopaedics Company of Johnson & Johnson**, has received…
R&D Postdoctoral Challenge is a ground-breaking initiative fostering collaboration, innovation and global diversity
R&D Postdoctoral Challenge is a ground-breaking initiative fostering collaboration, innovation and global diversity AstraZeneca announced today eight winners of the 2023 R&D Postdoctoral Challenge and agreed to fund their postdoctoral positions at…
.S. FDA Approves Pfizer’s VELSIPITY™ for Adults with Moderately to Severely Active Ulcerative Colitis
.S. FDA Approves Pfizer’s VELSIPITY™ for Adults with Moderately to Severely Active Ulcerative Colitis (UC) Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has…
U.S. FDA Approves Pfizer’s BRAFTOVI® + MEKTOVI® for BRAF V600E-Mutant Metastatic Non-Small Cell Lung Cancer
U.S. FDA Approves Pfizer’s BRAFTOVI® + MEKTOVI® for BRAF V600E-Mutant Metastatic Non-Small Cell Lung Cancer Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has…
Bayer invests 250 million USD in new cell therapy manufacturing facility in the U.S.
Bayer invests 250 million USD in new cell therapy manufacturing facility in the U.S. Bayer AG has opened a new cell therapy production plant in Berkeley, California, USA, to bring…
Merck Highlights Innovative Oncology Portfolio and Pipeline at ESMO Congress 2023 Underscoring Commitment to Advancing Cancer Research and Improving Patient Outcomes Across Multiple Stages of Disease
Merck Highlights Innovative Oncology Portfolio and Pipeline at ESMO Congress 2023 Underscoring Commitment to Advancing Cancer Research and Improving Patient Outcomes Across Multiple Stages of Disease Merck (NYSE: MRK), known…
Merck Announces Pivotal KEYNOTE-671 Trial Meets Dual Primary Endpoint of Overall Survival in Resectable Stage II, IIIA or IIIB Non-Small Cell Lung Cancer
Merck Announces Pivotal KEYNOTE-671 Trial Meets Dual Primary Endpoint of Overall Survival (OS) in Resectable Stage II, IIIA or IIIB Non-Small Cell Lung Cancer (NSCLC) Merck (NYSE: MRK), known as…
Roche’s Vabysmo maintained vision improvements with extended treatment intervals up to four months for people with retinal vein occlusion (RVO) in phase III studies
Roche’s Vabysmo maintained vision improvements with extended treatment intervals up to four months for people with retinal vein occlusion (RVO) in phase III studies Roche (SIX: RO, ROG; OTCQX: RHHBY)…
Janssen Highlights Latest Research for TREMFYA and Investigational Targeted Oral Peptide JNJ-2113 in Moderate to Severe Plaque Psoriasis at the European Academy of Dermatology and Venereology Congress
Janssen Highlights Latest Research for TREMFYA® (guselkumab) and Investigational Targeted Oral Peptide JNJ-2113 in Moderate to Severe Plaque Psoriasis at the European Academy of Dermatology and Venereology (EADV) Congress Janssen Pharmaceuticals,…
Anebulo Pharmaceuticals Announces New CEO
Anebulo Pharmaceuticals Announces New CEO Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB) (“Anebulo”), a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid intoxication (“ACI”), today announced that Richie Cunningham…
RevBio Awarded a $3.4 Million NIH Grant for Its Novel Regenerative Bone Adhesive to Treat Complex Fractures
RevBio Awarded a $3.4 Million NIH Grant for Its Novel Regenerative Bone Adhesive to Treat Complex Fractures RevBio, Inc., announced that it has been awarded a grant from the National…